Harmony Biosciences HoldingsHRMY
▲ PositiveCapitalrelevance
Q2 earnings and revenue beat, raised guidance
Impact on stocks 1
Biotech & Genomic Medicine
Harmony Biosciences HoldingsHarmony Biosciences Holdings reported second-quarter earnings that increased from a year ago. Net income rose to $75.43 million, or $1.28 per share, compared with $39.78 million, or $0.68 per share, in the same period last year. Revenue grew 30.3% to $261.28 million from $200.49 million. The company issued full-year revenue guidance of $1.0 billion to $1.04 billion.
Harmony Biosciences HoldingsQ2 earnings and revenue beat, raised guidance